SVB Securities analyst Roanna Ruiz reiterated a Buy rating on ARS Pharmaceuticals (SPRY – Research Report) on January 6 and set a price target of $14.00. The company’s shares closed last Friday at $7.23.
Ruiz covers the Healthcare sector, focusing on stocks such as Lantheus, scPharmaceuticals, and Amarin. According to TipRanks, Ruiz has an average return of -39.4% and a 18.52% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ARS Pharmaceuticals with a $15.50 average price target, an 114.38% upside from current levels. In a report released on January 3, William Blair also initiated coverage with a Buy rating on the stock with a $17.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $9.17 and a one-year low of $2.80. Currently, ARS Pharmaceuticals has an average volume of 217.2K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SPRY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
Read More on SPRY:
